Therapeutic Insights
Filter News
Found 238 articles
-
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Investigators from the Cleveland Clinic assessed possible relationships between COVID-19 and neuroinflammation and brain microvascular injury – two hallmarks of AD.
-
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors
6/14/2021
Cassava Sciences, Inc. today announced the appointment of Mr. Richard (Rick) Barry to the Company’s Board of Directors, effective June 11, 2021.
-
Aaron Kesselheim, a professor of Medicine at Harvard Medical School and has served on the advisory committee since 2015, has stepped down.
-
This is the first confirmation of elemental metals in human brain tissue. Researchers hope it can contribute to the ongoing Herculean task of finding a cure for Parkinson's and Alzheimer's.
-
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
-
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
6/10/2021
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease.
-
In a conference call on Wednesday, Biogen CEO Michel Vounatsos outlined the company's plans for commercial distribution of Aduhelm.
-
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
6/9/2021
Synaptogenix, Inc. today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial f Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease.
-
Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease
6/9/2021
Halberd Corporation (OTC PINK:HALB) commences experimentations to eradicate three of the principal components of Alzheimer's Disease.
-
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
-
Despite controversy over the drug’s effectiveness, it appears to have spiked interest in investing in Alzheimer’s drug companies, something that had been on the decline for several years.
-
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
6/8/2021
ProMIS Neurosciences, Inc. today congratulates Biogen on the recent FDA approval of its monoclonal antibody therapeutic, aducanumab.